Ceribell's Q2 Loss Widens to $15.3M Despite 22.5% Revenue Jump
Ticker: CBLL · Form: 10-Q · Filed: Aug 5, 2025 · CIK: 1861107
| Field | Detail |
|---|---|
| Company | Ceribell, INC. (CBLL) |
| Form Type | 10-Q |
| Filed Date | Aug 5, 2025 |
| Risk Level | high |
| Sentiment | mixed |
Sentiment: mixed
Topics: Medical Devices, Neurology, EEG Technology, Biotechnology, Growth Stock, Loss-Making Company, Capital Raise
Related Tickers: CBLL
TL;DR
**Ceribell's revenue growth is promising, but widening losses mean it's still a speculative bet for now.**
AI Summary
Ceribell, Inc. reported a net loss of $15.3 million for the three months ended June 30, 2025, compared to a net loss of $14.8 million for the same period in 2024, representing a 3.4% increase in loss. Revenue for the three months ended June 30, 2025, was $12.5 million, up from $10.2 million in the prior year, a 22.5% increase, primarily driven by product and subscription sales. For the six months ended June 30, 2025, the net loss was $30.1 million, a slight increase from $29.5 million in the first half of 2024. The company secured a new term loan facility of up to $50.0 million on February 6, 2024, with Silicon Valley Bank, replacing a previous facility and providing additional liquidity. Strategic outlook includes continued investment in product development and market expansion, with a focus on increasing subscription revenue. Risks include ongoing net losses and the need for future capital to fund operations, as evidenced by accumulated deficit of $344.0 million as of June 30, 2025.
Why It Matters
Ceribell's continued revenue growth, up 22.5% to $12.5 million, signals strong market adoption for its EEG technology, which is crucial for investors evaluating its long-term viability in the competitive medical device sector. However, the widening net loss to $15.3 million raises concerns about profitability and cash burn, impacting investor confidence and potentially necessitating further capital raises. For employees, sustained losses could lead to future restructuring, while customers benefit from continued innovation in neurological diagnostics. The broader market watches Ceribell as a bellwether for innovation in electroencephalography, with its performance influencing investment in similar med-tech startups.
Risk Assessment
Risk Level: high — Ceribell reported an accumulated deficit of $344.0 million as of June 30, 2025, and a net loss of $15.3 million for the quarter, indicating significant ongoing losses. The company's ability to continue as a going concern is dependent on its ability to obtain additional financing, which presents a high financial risk.
Analyst Insight
Investors should monitor Ceribell's cash burn rate and future financing activities closely. While revenue growth is positive, the persistent net losses and accumulated deficit suggest a need for significant capital, so consider this a high-risk, high-reward investment.
Financial Highlights
- revenue
- $12.5M
- net Income
- -$15.3M
- revenue Growth
- +22.5%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Product and Subscription Sales | $12.5M | +22.5% |
Key Numbers
- $12.5M — Q2 2025 Revenue (Increased 22.5% from $10.2M in Q2 2024, driven by product and subscription sales.)
- $15.3M — Q2 2025 Net Loss (Widened from $14.8M in Q2 2024, indicating increased operational costs despite revenue growth.)
- $344.0M — Accumulated Deficit (As of June 30, 2025, highlighting significant historical losses and the need for future capital.)
- 22.5% — Revenue Growth (Year-over-year increase in Q2 2025 revenue, demonstrating market traction.)
- $50.0M — Term Loan Facility (Secured on February 6, 2024, providing crucial liquidity for operations.)
Key Players & Entities
- Ceribell, Inc. (company) — filer of the 10-Q
- Silicon Valley Bank (company) — lender for the $50.0 million term loan
- $15.3 million (dollar_amount) — net loss for Q2 2025
- $14.8 million (dollar_amount) — net loss for Q2 2024
- $12.5 million (dollar_amount) — revenue for Q2 2025
- $10.2 million (dollar_amount) — revenue for Q2 2024
- $30.1 million (dollar_amount) — net loss for the six months ended June 30, 2025
- $29.5 million (dollar_amount) — net loss for the six months ended June 30, 2024
- $50.0 million (dollar_amount) — maximum amount of the new term loan facility
- $344.0 million (dollar_amount) — accumulated deficit as of June 30, 2025
FAQ
What were Ceribell's key financial results for the second quarter of 2025?
Ceribell, Inc. reported revenue of $12.5 million for the three months ended June 30, 2025, a 22.5% increase from $10.2 million in the prior year. The net loss for the quarter was $15.3 million, compared to a net loss of $14.8 million for the same period in 2024.
How has Ceribell's net loss changed year-over-year?
For the three months ended June 30, 2025, Ceribell's net loss increased to $15.3 million from $14.8 million in the same period of 2024, representing a 3.4% increase in loss. For the six months ended June 30, 2025, the net loss was $30.1 million, a slight increase from $29.5 million in the first half of 2024.
What is Ceribell's accumulated deficit as of June 30, 2025?
As of June 30, 2025, Ceribell, Inc. reported an accumulated deficit of $344.0 million, indicating significant historical losses since its inception.
What strategic financing did Ceribell secure in 2024?
On February 6, 2024, Ceribell secured a new term loan facility of up to $50.0 million with Silicon Valley Bank, which replaced a previous facility and provided additional capital for operations.
What are the primary risks for Ceribell investors?
Primary risks for Ceribell investors include the company's persistent net losses, an accumulated deficit of $344.0 million, and the ongoing need for future capital to fund operations, which could dilute existing shareholders.
How does Ceribell generate its revenue?
Ceribell generates its revenue primarily through product sales and subscription services related to its EEG technology, as evidenced by the revenue growth in these segments for the three and six months ended June 30, 2025.
What is the outlook for Ceribell's future operations?
Ceribell's outlook involves continued investment in product development and market expansion, with a strategic focus on increasing subscription revenue. However, the company acknowledges the need for future capital to sustain these operations.
What is the significance of the 22.5% revenue increase for Ceribell?
The 22.5% revenue increase to $12.5 million for Q2 2025 signifies strong market adoption and demand for Ceribell's EEG products and services, demonstrating positive traction in its target market.
Did Ceribell mention any significant subsequent events after June 30, 2025?
The filing mentions a subsequent event related to the 'One Big Beautiful Bill Act' on July 4, 2025, though specific details of its impact on Ceribell are not provided in the summary data.
What is Ceribell's business address and phone number?
Ceribell, Inc.'s business address is 360 N. Pastoria Avenue, Sunnyvale, CA 94085, and its business phone number is (800) 436-0826.
Risk Factors
- Ongoing Net Losses and Capital Requirements [high — financial]: Ceribell reported a net loss of $15.3 million for Q2 2025, an increase from $14.8 million in Q2 2024. The company has an accumulated deficit of $344.0 million as of June 30, 2025, indicating a substantial need for future capital to fund operations and continued growth.
- Dependence on Debt Financing [medium — financial]: The company secured a $50.0 million term loan facility with Silicon Valley Bank on February 6, 2024. While this provides liquidity, it also increases the company's debt obligations and reliance on external financing to sustain operations.
- Increased Operating Costs [medium — operational]: Despite a 22.5% increase in revenue for Q2 2025, the net loss widened by 3.4% to $15.3 million. This suggests that operating costs are increasing at a faster rate than revenue, potentially impacting profitability.
- Market Expansion and Product Development Investment [medium — market]: The company's strategic outlook includes continued investment in product development and market expansion. While necessary for growth, these investments require significant capital and may not yield immediate returns, adding to the financial strain.
Industry Context
Ceribell operates in the electromedical and electrotherapeutic apparatus industry, a sector characterized by rapid technological advancements and significant R&D investment. The market for medical devices, particularly those focused on diagnostics and monitoring like Ceribell's offerings, is competitive and driven by innovation, regulatory approvals, and adoption by healthcare providers.
Regulatory Implications
As a medical device company, Ceribell is subject to stringent regulatory oversight from bodies like the FDA. Compliance with manufacturing standards, product safety, and marketing regulations is critical. Any delays or failures in regulatory processes can significantly impact product launch timelines and market access.
What Investors Should Do
- Monitor revenue growth drivers and subscription revenue trends.
- Assess the company's cash burn rate and future financing needs.
- Evaluate the impact of increased operating costs on profitability.
Key Dates
- 2024-02-06: Secured new $50.0 million term loan facility with Silicon Valley Bank. — Provides crucial additional liquidity to fund operations and strategic initiatives, replacing a previous facility.
- 2025-06-30: End of the second quarter for the reported 10-Q. — Represents the period for which financial results and operational updates are provided.
Glossary
- Accumulated Deficit
- The total cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates the company's historical unprofitability and its need for ongoing capital to sustain operations.)
- Term Loan Facility
- A type of loan provided by a financial institution, typically for a specific period and with a defined repayment schedule. (Represents a significant source of funding for Ceribell, impacting its debt structure and liquidity.)
- Restricted Stock Units (RSUs)
- A form of equity compensation granted to employees that vests over time or upon meeting certain performance conditions. (Part of executive and employee compensation, impacting share dilution and future expenses.)
Year-Over-Year Comparison
Ceribell's Q2 2025 results show continued revenue growth of 22.5% year-over-year, driven by product and subscription sales. However, this growth is accompanied by a widening net loss, up 3.4% to $15.3 million, indicating increased operational costs. The company has secured a significant $50.0 million term loan facility, providing liquidity but also increasing its debt burden. The accumulated deficit remains substantial at $344.0 million, highlighting ongoing financial challenges.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on August 5, 2025 regarding Ceribell, Inc. (CBLL).